Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...

In a landmark trial, Eli Lilly's obesity drug Zepbound surpassed Novo Nordisk's Wegovy, showing 47% more weight loss. The ...

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly ...

Eli Lilly's obesity drug Zepbound showed 47% more weight loss than Novo Nordisk's Wegovy in a major comparative trial. The ...